INCEPTION

Virago was founded in 2018 with the primary mission of ending breast cancer in our lifetime. The founding partners met and forged their relationships through a series of happy accidents that proved fated to provoke innovation and focus problem solving. A mixture of physicians and entrepreneurs, we examined existing inefficiencies in the clinical approach to breast cancer (i.e., treatment vs. prevention), as well as the relevant and often undervalued sociological aspects of the problem (environmental exposure, access to care, etc..).

In the early phases of our research, we recognized that the virus that potentially causes breast cancer is also, and possibly equally, implicated in prostate cancer. We therefore broadened our scope and set out to address both growing epidemics simultaneously, taking into consideration the impact of multiple viral agents on multiple forms of cancer.

GROWTH

Over the course of 2019, Virago established pivotal partnerships and achieved tremendous growth. The company’s researchers identified optimal targets for vaccine production, and submitted its initial foundational patent for the corresponding intellectual property (US 2019-0343938). The vaccine design was accepted into the Cancer Immunotherapy Pilot Program, as a special designation conferred upon products with exceptional potential as cancer therapeutics. The company is currently patent pending for preventative and therapeutic vaccines in humans and pets (US20190343938A1 and US20210000800A1).

GOALS

Virago Vax seeks to explore tumor viruses and their role across diseases and across species. By shifting the conversation from treatment to prevention, we hope to gain insight into a more definitive approach to cancer elimination. This methodology involves reframing the cancer conversation with a new perspective in hopes of achieving our ultimate goal: Powerful vaccines and the end of these diseases within a generation.

to contact us, please email: drsophie@viragofoundation.org